B-Cell Malignancies: CAR-T Cell Therapy Study

We are testing a new CAR-T cell treatment for patients with relapsed and refractory B-cell cancers. The goal is to find a safe dose and understand how well it works.

1-2 yearsSafety phase (I)HematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Technische Universitat Dresden
Nationales Zentrum für Tumorerkrankungen Dresden (NCT/UCC), Early Clinical Trial Unit
Dresden, Germany
Sponsor: Technische Universitat Dresden
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.